Estrella Immunopharma, Inc. (ESLA) Research

Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.

Market snapshot

Symbol
ESLA
Price
$0.95
Day change
-5.94%
Market cap
$40.9M
P/E ratio
-3.02x
52-week range
0.78-3.15
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Anebulo Pharmaceuticals, Inc. (ANEB)
  • Atossa Therapeutics, Inc. (ATOS)
  • eXoZymes, Inc. (EXOZ)
  • Greenwich LifeSciences, Inc. (GLSI)
  • Immix Biopharma, Inc. (IMMX)
  • Oncolytics Biotech Inc. (ONCY)
  • Surrozen, Inc. (SRZN)
  • Instil Bio, Inc. (TIL)

Recent insider activity

  • Xu Jiandong — P-Purchase (1000 shares) on 2025-10-07
  • Xu Jiandong — P-Purchase (100 shares) on 2025-09-11
  • Xu Jiandong — P-Purchase (1000 shares) on 2025-09-22
  • Jia Dengyao — trade (0 shares) on 2025-09-22
  • Liu Cheng — A-Award (509204 shares) on 2024-10-30

Open Estrella Immunopharma, Inc. (ESLA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.